Abstracts tagged "biologic refractory disease"

Abstract Number: 0844 • ACR Convergence 2021
Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort
Stephanie Keeling¹, Britney Jones², Jill Hall³, Joanne Homik⁴, Anthony Russell¹, Luck Lukusa⁵, Sasha Bernatsky⁶ and Walter Maksymowych⁷, ¹Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ²University of Alberta/University of Calgary, Edmonton, AB, Canada, ³Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶McGill University, Montréal, QC, Canada, ⁷Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) experience refractory disease and do not attain remission imparting worse long-term outcomes. We evaluated RA patients…